Clinical trial
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell…
NCT00220285 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00220285 |
|---|---|
| Title | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Lymphoma, B-Cell, Low-Grade |
| Intervention type | Drug |
| Interventions | Zevalin (SH L 749, BAY86-5128) |
| Enrollment | 45 |
| Start date | Aug 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 30, 2014 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: